The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation

doi:10.1016/j.ajur.2022.02.002

Asian Journal of Urology, 2022, 9 (4): 480-482 doi: 10.1016/j.ajur.2022.02.002

Regular Papers: Letter

Current Issue | Archive | Adv Search

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation

Hiroshi Hongo^a,Takeo Kosaka^a,*(

),Kohei Nakamura^b,Shuji Mikami^c,Hiroshi Nishihara^d,Mototsugu Oya^a

^aDepartment of Urology, Keio University School of Medicine, Japan
^bGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Japan
^cDepartment of Diagnostic Pathology, Keio University Hospital, Japan
^dGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Japan

Abstract
Related Citation (0)

[1]	Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 2011; 32:894e9.
[2]	Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015; 163:1011e25.
[3]	Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, et al. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation. Pathol Int 2019; 69:715e20.
[4]	Hongo H, Kosaka T, Aimono E, Nishihara H, Oya M. Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagn Pathol 2020; 15:5. https://doi.org/10.1186/s13000-019-0916-z.
[5]	Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol 2019; 249:79e89.
[6]	Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncol 2019; 5:51e7.
[7]	Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016; 375: 443e53.
[8]	Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez- Lopez R, et al. DNA-defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373:1697e708.
[9]	Neychev V, Sadowski SM, Zhu J, Allgaeuer M, Kilian K, Meltzer P, et al. Neuroendocrine tumor of the pancreas as a manifestation of Cowden syndrome: a case report. J Clin Endocrinol Metab 2016; 101:353e8.
[10]	González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 2014; 4:896e904.